Sell-side analysts that cover Tobira Therapeutics, Inc. (NASDAQ:TBRA) are expecting the company to report earnings for the quarter of $-0.63. The consensus estimate uses covering analysts polled by Zacks Research. The estimate may vary from what other data providers have for the quarterly consensus. Most recently, the company posted quarterly earnings per share of $-0.71 for the period ending on 2016-06-30. The result came in $-0.1 separated from the Zacks consensus estimate which caused a surprise factor of -16.39%. When a company posts a noticable surprise factor, either negative or positive, substantial stock price moves might be seen in the days after the report.
In taking a look at where analysts believe Tobira Therapeutics, Inc. (NASDAQ:TBRA) is headed, the covering brokerages have a one year target price of $19 on the shares. This is based on the 4 analysts polled by Zacks Research. The analyst with the most aggressive viewpoint sees the stock heading towards $31 within the next 12 months while the most bearish sees the shares going to $11 in that same timeframe. The most recent analyst revision occurred on 2016-08-19. Depending on the brokerage firm, analysts on the sell-side use alternate terminology to describe their Buy/Sell recommendations.
Retail investors not familiar with a particular firms reports could find the recommendations difficult to understand. As a result, Zacks offers an analyst brokerage rating (ABR) which simplifies the recommendations into a 1 to 5 sliding scale where one represents a Strong Buy and 5 indicates a Strong Sell. Tobira Therapeutics, Inc. (NASDAQ:TBRA) currently has an ABR 1.5. This is the average recommendation based on the 4 analysts polled.
Please note that the data derived in this report is from Zacks Research. This is not a recommendation to Buy or Sell shares of Tobira Therapeutics, Inc.. The author of this article does not hold any position in the company. Investors should conduct their own thorough research before buying or selling equities.